ReACH Achondroplasia Registry
csen
 
 

For physicians

A rapid development of achondroplasia treatment raises the possibility that patients of Mid European region might be able to participate in the ongoing clinical testing. However the incidence rates as well as other aspects of achondroplasia epidemiology in the Czech Republic are unknown. These are critical parameters that will determine the future planning of the clinical testing in the given region. To fill this void, we created the Registry of Achondroplasia (ReACH). The Registry will collect information necessary for future clinical research in Achondroplasia. This includes clinical testing of the new treatment. While we cannot guarantee these achondroplasia treatments will be tested in the Czech Republic, we plan to use the Registry data to facilitate the potential access of achondroplasia patients to these newly developed treatments. This is one of the main reasons why we invite physicians managing achondroplasia patients to enroll their patients in ReACH.